|Número de publicación||WO1994023038 A1|
|Tipo de publicación||Solicitud|
|Número de solicitud||PCT/GB1994/000621|
|Fecha de publicación||13 Oct 1994|
|Fecha de presentación||25 Mar 1994|
|Fecha de prioridad||26 Mar 1993|
|Número de publicación||PCT/1994/621, PCT/GB/1994/000621, PCT/GB/1994/00621, PCT/GB/94/000621, PCT/GB/94/00621, PCT/GB1994/000621, PCT/GB1994/00621, PCT/GB1994000621, PCT/GB199400621, PCT/GB94/000621, PCT/GB94/00621, PCT/GB94000621, PCT/GB9400621, WO 1994/023038 A1, WO 1994023038 A1, WO 1994023038A1, WO 9423038 A1, WO 9423038A1, WO-A1-1994023038, WO-A1-9423038, WO1994/023038A1, WO1994023038 A1, WO1994023038A1, WO9423038 A1, WO9423038A1|
|Inventores||Salvador Enrique Moncada, Ian George Charles, Richard Michael John Palmer|
|Solicitante||The Wellcome Foundation Limited|
|Exportar cita||BiBTeX, EndNote, RefMan|
|Otras citas (5), Citada por (21), Clasificaciones (10), Eventos legales (6)|
|Enlaces externos: Patentscope, Espacenet|
INDUCIBLE NITRIC OXIDE SYNTHASE AND GENE THEREFOR.
The invention relates to a novel nitric oxide (NO) synthase, DNA coding therefor, methods for detection of the NO synthase and the DNA, a method for screening for compounds capable of inhibiting or stimulating the NO synthase, and the compounds thereby identified.
The demonstration in 1987 of the formation of NO by an enzyme in vascular endothelial cells opened up what can now be considered as a new area of research (for review, see Moncada e_t al. (1991) Pharmacological Reviews, vol. 43, no. 2, 109-142) . NO is synthesised from the amino acid L-arginine by the enzyme NO synthase.
The synthesis of NO from L-arginine by NO synthase is now recognized as an important pathway for regulating the function of a wide variety of cells and tissues. For example, in the blood vessel wall, NO is synthesised by the vascular endothelium to regulate smooth muscle tone and thus blood pressure. Nitric oxide synthase is also present in the central nervous system, where NO is a neurotransmitter/neuromodulator mediating the action of glutamate on NMDA receptors and mediating/modulating transmission in nerves previously recognised as nonadrenergic and noncholinergic. NO can also act as an autocrine regulator on some cells, including platelets, where it modulates their activation. NO generated by activated macrophages is also an important effector molecule in host defence. In this role, NO has been shown to possess anti-tumour and anti-microbial activity against various parasites in vitro and in vivo.
NO synthases can be classified into two types, namely inducible and constitutive NO synthases. NO synthase activity is constitutively expressed in a variety of cells including endothelial cells, neurons, platelets, adrenal gland cells, and endocardium cells. In contrast, NO synthase is inducible in macrophages, hepatocytes, Kupffer cells, vascular smooth muscle and vascular endothelium following activation with endotoxin and/or cyto ines. More recently, NO synthase has been shown to be induced in rabbit articular chondrocytes (Stadler e_£. al- (1991) J. Immunol. 147. 3915-3920 and Palmer e£ al. (1992) Biochem. Biophys. Res. Commun. 188. 209-215) . We have observed that in human chondrocytes the enzyme is induced by interleukin-lβ (IL-lβ) . The induction of NO synthase in human cells has previously only been reliably shown in hepatocytes (Nussler e_t al (1992), J. Exp. Med. 176. 261-264) . The induction of NO synthase in chondrocytes is likely to have a role in joint disease (i.e. arthritic disease) . IL-lβ concentrations are increased in the inflamed joint and under these conditions NO synthase is likely to be induced.
The NO synthase enzymes comprise a family that can be distinguished on the basis of comparative DNA sequence analysis. Sequences have been reported for the constitutive neuronal NO synthase cDNAs from rat and man (Bredt e_L al.
(1991) Nature 3_5L, 714-718 and Nakane ei al. (1993) Febs. Lett. 3_16_, 175-180) , the constitutive endothelial NO synthase cDNAs from bovine and human tissue (Lamas e_£. al. (1992) Proc. Natl. Acad. Sci. USA 89, 6348-6352; Janssens e_£. al. (1992) J. Biol Chem. 267. 14519-14522; Sessa ei al. (1992) J. Biol. Chem. 267. 15274-15276; Marsden ejt al- (1992) Febs. Lett. 307. 287-293) and an inducible NO synthase cDNA from a rodent macrophage line
(Lyons ei al. (1992) J. Biol. Chem. 2£2, 6370-6374; Xie ei al.
(1992) Science 256. 225-228; and Lowenstein e_t al. (1992) Proc. Natl. Acad. Sci. USA 89, 6711-6715) . A comparison of the deduced protein sequences derived from the three classes of NO synthase enzymes shows, overall, approximately 50-60% similarly. For all three enzymes, the highest degree of similarity occurs around a conserved region within the first third of the molecule, thought to represent the L-arginine binding site.
Although two distinct forms of the constitutive enzyme have been described at the molecular level, with high identity between the rat, and human neuronal forms and between the bovine and human endothelial forms, only the murine macrophage form of the inducible NO synthase has been similarly characterized.
In the present invention, a novel human inducible NO synthase has been characterized. The full length cDNA encoding the NO synthase has been cloned and expressed using human articular chondrocytes activated with IL-lβ. The NO synthase enzyme has utility in a number of settings as described hereinafter, but is of particular value in a research environment in which it can be used in a screen or assay to identify compounds that are capable of inhibiting or stimulating the activity of the enzyme. Such compounds have utility in the clinic for the treatment of indications as described hereinafter.
The present invention provides an NO synthase having the sequence of SEQ ID NO: 2, or an NO synthase having a sequence at least 85% identical to the sequence of SEQ ID NO: 2. The NO synthase may, for example, have a sequence at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 2. The NO synthase is generally of human origin, preferably human chondrocyte origin.
The expression 'NO synthase1 includes the full length cDNA encoding the NO synthase and any fragment thereof. The fragment of the NO synthase may be a fragment at least 6 amino acids in length. The length of the fragment may be, for example, at least 8, at least 12, at least 24, at least 48 or at least 96 amino acids, and is intended to include the fragment corresponding to the active domain of the enzyme, i.e. the domain which catalyses the synthesis of NO from L-arginine.
The NO synthase is generally in substantially pure form. Preferably, the NO synthase in substantially pure form comprises a preparation in which at least 90%, at least 95%, at least 98% or at least 99% of the weight of protein in the preparation is the NO synthase of the invention.
The NO synthase will usually be obtained by recombinant DNA techniques. However, the NO synthase may be obtained using biochemical purification of the protein from its natural origin.
The invention provides a DNA molecule encoding the NO synthase. The DNA molecule may contain the sequence of nucleotides 226 to 3687 of SEQ ID NO: 1. Alternatively, the DNA molecule may contain a sequence at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to the sequence of nucleotides 226 to 3687 of SEQ ID NO: 1.
A person of ordinary skill in the art would know how to obtain a DNA molecule according to the invention using the sequences disclosed herein, without undue experimentation. The DNA molecules according to the invention could be produced by various means, such as, for example, DNA synthesis, or more preferably, by recombinant DNA techniques. Techniques for synthesising DNA molecules are described by, for example, Wu e_£ al (Prog. Nucl. Acid. Res. Molec. Biol. 21, 101-141 (1978)) . Techniques for constructing recombinant molecules are described by Sambrook __________ al (1989) Molecular Cloning: A Laboratory
Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
The present NO synthase may be obtained by making a library of replicable expression vectors. The library may be created by cloning genomic DNA or, more preferably, cDNA into a parent vector. The cDNA may be obtained using the poly A+ mRNA of a cell (e.g. a chondrocyte) in which NO synthase production has been induced, e.g. by a cytokine such as IL-lβ. The library is screened for members containing the desired nucleic acid sequence, e.g. by means of a DNA probe or antibody. A probe having a sequence identical to a portion of the sequence of nucleotides 226 to 3687 of SEQ ID NO: 1 or exactly complementary to a portion of the sequence nucleotides 226 to 3687 of SEQ ID NO: 1 may be used to identify an NO synthase coding sequence not identical to the sequence of nucleotides 226 to 3687 of SEQ ID NO: 1 (e.g. from 85% to 99% identical to nucleotides 226 to 3687 of SEQ ID NO: 1) by low stringency hybridization.
A replicable expression vector is a vector which contains the appropriate origin of replication sequence for replication of the vector and the appropriate sequences for expression of the foreign nucleotide sequence in the vector. The sequences for expression of a foreign sequence will generally include a transcription promoter operably linked to the foreign sequence. The term "operably linked" refers to a linkage in which the promoter and foreign sequence are connected in such a way to permit expression of the foreign sequence. The transcription promoter sequence may be part of the parent vector sequence into which the foreign sequence is inserted. Alternatively, the promoter sequence may be a native promoter sequence of a gene encoding an NO synthase of the invention, so that the NO synthase is inducible by IL-lβ. A vector may be, for example, a plasmid, virus or phage vector. A vector may contain one or more selectable markers, for example an ampicillin resistance gene in the case of a bacterial vector or a neomycin resistance gene in the case of a mammalian vector. A foreign gene sequence inserted into a vector may be transcribed in vitro or the vector may be used to transform or transfect a host cell.
According to one embodiment of the invention, there is provided a host cell transformed or transfected with a vector. A vector and host cell will be chosen so as to be compatible with each other, and may be prokaryotic or eukaryotic. A prokaryotic host may, for example, be E. coli. in which case the vector may, for example, be a bacterial plasmid or a phage vector. A eukaryotic host may, for example, be a yeast (e.g. S. cerevisiae) a Chinese hamster ovary (CHO) cell or an insect cell (e.g. Spodpptera frugiperda) . When the host is an insect cell, the vector is generally a baculovirus vector (reviewed by Luckow and Summers (1988) in BIO/TECHNOLOGY, Vol. 6, 47-55) .
An NO synthase according to the invention may be produced by a method comprising
(a) culturing a host cell under conditions in which the cell expresses the NO synthase; and (b) recovering the NO synthase from the culture.
In this method, expression of NO synthase may be induced by a cytokine such as IL-lβ. The NO synthase may be recovered from either the host cell or, where the NO synthase is secreted by the host cell, from the culture supernatant.
The invention includes a an oligonucleotide fragment having a sequence of a portion of a DNA molecule encoding an NO synthase of the invention, and an oligonucleotide fragment having a sequence at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%, identical to a sequence encoding an NO synthase of the invention or fragment thereof. The fragment is at least 12 nucleotides in length, e.g. at least 15, at least 18, at least 30, at least 60, at least 180, or at least 720 nucleotides in length. The fragment may be single or double stranded. When the fragment is single stranded, it may have a sequence from either a sense or antisense strand of a DNA molecule encoding an NO synthase of the invention. An antisense fragment may be useful in the therapeutic treatment of a disease involving over-expression of NO synthase, whilst a full-length expression fragment may be of use in treatment of conditions requiring stimulation of the NO synthase, for example treatment of some viral diseases or solid tumours.
The fragment will generally be DNA, although other types of nucleic acid may be used, for example RNA or modified DNA. A number of different types of nucleic acid modification are known in the art. These include methylphosphonate and phosphorothioate backbones, and addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule.
The oligonucleotide fragment may be an oligonucleotide probe or an oligonucleotide polymerase chain reaction (PCR) primer, which will hybridise to a nucleic acid molecule (e.g. a DNA or RNA molecule) encoding an NO synthase of the invention. The probe or a pair of primers may be used to detect or quantitatively determine the nucleic acid sequence. This has diagnostic utility in detecting and quantitatively determining NO synthase mRNA associated with a disease state, for example arthritic disease, high blood pressure, disorders of the central nervous system, and cancers such as breast cancer.
A fragment which is a probe or primer may carry a revealing label, such as 32P, digoxigenin or biotin. Preferably, the probe or primer will specifically hybridise only to its target sequence, e.g. a portion of SEQ ID NO: 1, and not to other sequences. However, it will be appreciated that this will not always be the case, and the probe or primer may only be selective for its target sequence. A probe or primer which hybridises only to its target sequence will generally be exactly complementary to the target sequence (e.g. a portion of the sequence of nucleotides 226 to 3687 of SEQ ID NO: 1) whereas a probe or primer which is only selective may have a sequence which is, for example, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% complementary to the target sequence. A probe which is not exactly complementary to its target sequence has utility in the identification of new NO synthase nucleotide sequences having a sequence similar to the sequence of nucleotides 226 to 3687 of SEQ ID NO: 1. A fragment which is a probe or primer may have from 12 to 60 nucleotides, e.g. from 12 to 40 nucleotides, or from 15 to 30 nucleotides.
Primers for PCR are generally provided as a pair. A first primer hybridises to a sense sequence 3 ' to the sequence to be amplified and a second primer hybridises to an antisense sequence 5' to the sequence to be amplified. This allows synthesis of double stranded DNA representing the region between the two primers.
Thus, the invention includes a method of amplifying a target nucleic acid sequence present in a nucleic acid encoding an NO synthase of the invention, which method comprises carrying out PCR employing a primer of the invention. Such a method generally comprises carrying out cycles of
(a) denaturing double stranded DNA containing the target sequence to obtain single stranded DNA; (b) hybridizing a first primer to a sense strand 3' to the target sequence, and hybridising a second primer to an antisense strand 5 ' to the target sequence; and
(c) synthesising DNA from the first and second primers.
The number of cycles is suitably from 10 to 50, preferably 20 to 40, more preferably 25 to 35. The method may be carried out starting from a double stranded nucleic acid (e.g. dsDNA) or a single stranded nucleic acid (e.g. mRNA) . The target sequence may be a complete NO synthase encoding sequence or a partial NO synthase encoding sequence.
As will be appreciated by a person skilled in the art, the method described above is based upon the well-known polymerase chain reaction (PCR) method. A skilled person would know of detailed protocols for carrying out PCR and reverse transcriptase-PCR (RT-PCR) . Reviews of PCR are provided by Mullis (1986) Cold Spring Harbor Symp. Quant. Biol. 51, 263- 273; Saiki e_L al. (1985) Bio/Technology 3, 1008-1012; and Mullis fit al (1987) Meth. Enzymol 155, 335-350.
An oligonucleotide probe according to the invention has utility in detecting or quantitatively determining a nucleic acid (e.g. a DNA or RNA) encoding an NO synthase according to the invention. Conventional methods for detecting or quantitatively determining a nucleic acid may be used, for example in situ hybridization, Southern blotting or Northern blotting. Accordingly, there is provided a method of detecting or quantitatively determining in a sample a target nucleic acid sequence present in a nucleic acid encoding an NO synthase according to the invention, which method comprises
(a) contacting the probe with the sample; and
(b) detecting or quantitatively determining hybridization of the probe with any target nucleic acid sequence present in the sample.
The sample containing the target nucleotide sequence may, for example, be a tissue specimen, a tissue extract or cell extract from a patient suffering from a disease associated with abnormal NO synthase activity such as arthritis, high blood pressure, a disorder of the central nervous system, or a cancer such as breast cancer. Alternatively, the sample may, for example, be a sample produced as a result of a recombinant DNA procedure, in which case the sample may be a vector or an extract of host cells. The target nucleic acid sequence may be a complete NO synthase encoding sequence or a partial NO synthase encoding sequence.
A preferred method of detecting or quantitatively determining a target nucleic acid sequence in a sample comprises
(i) subjecting the sample to gel electrophoresis to separate the nucleic acids;
(ii) transferring the separated nucleic acids onto a solid support (e.g. a nitrocellulose support) by blotting; and
(iii) hybridising a probe according to the invention to the target nucleic acid sequence.
A probe can be used in an in situ hybridization procedure to locate a nucleic acid sequence encoding an NO synthase of the invention. This can be done to determine the spatial distribution of NO synthase encoding DNA or RNA sequences in a cell or tissue. In the case of mRNA detection, the tissue is gently fixed so that its RNA is retained in an exposed form and the tissue is then incubated with a labelled complementary probe.
A polypeptide fragment of the present invention has utility in, for example, producing antibodies against an NO synthase.
Thus, the invention includes an antibody specific for an NO synthase according to the invention. The antibody has utility in detecting and quantitatively determining NO synthases, and hence is useful in diagnosis of diseases associated with NO synthase, such as the diseases listed herein. An antibody of the present invention may also be of use in identifying which NO synthase enzyme is responsible for a particular condition. The antibody also has utility in production of NO synthases by recombinant DNA procedures, for example in detection of positive clones containing a target sequence. Furthermore, the antibody may be of use as a therapeutic agent.
The antibody is preferably monoclonal, but may also be polyclonal. The antibody may be labelled. Examples of suitable antibody labels include radiolabels, biotin (which may be detected by avidin or streptavidin conjugated to peroxidase), alkaline phosphatase and fluorescent labels (e.g. fluorescein and rhodamine) . The term "antibody" is used herein to include both complete antibody molecules and fragments thereof. Preferred fragments contain at least one antigen binding site, such as Fab and F(ab')2 fragments. Humanised and chimaeric antibodies and fragments thereof are also included within the term "antibody".
The antibody is produced by raising antibody in a host animal against an NO synthase according to the invention or an antigenic epitope thereof (hereinafter "the immunogen") . Methods of producing monoclonal and polyclonal antibodies are well-known. A method for producing a polyclonal antibody comprises immunising a suitable host animal, for example an experimental animal, with the immunogen and isolating immunoglobulins from the serum. The animal may therefore be inoculated with the immunogen, blood subsequently removed from the animal and the IgG fraction purified. A method for producing a monoclonal antibody comprises immortalising cells which produce the desired antibody. Hybridoma cells may be produced by fusing spleen cells from an inoculated experimental animal with tumour cells (Kohler and Milstein, Nature 256. 495- 497, 1975) .
An immortalized cell producing the desired antibody may be selected by a conventional procedure. The hybridomas may be grown in culture or injected intraperitoneally for formation of ascites fluid or into the blood stream of an allogenic host or immunocompromised host. Human antibody may be prepared by in vitro immunisation of human lymphocytes, followed by transformation of the lymphocytes with Epstein-Barr virus.
For the production of both monoclonal and polyclonal antibodies, the experimental animal is suitably a goat, rabbit, rat or mouse. If desired, the immunogen may be administered as a conjugate in which the immunogen is coupled, for example via a side chain of one of the amino acid residues, to a suitable carrier. The carrier molecule is typically a physiologically acceptable carrier. The antibody obtained may be isolated and, if desired, purified.
The invention includes a method of detecting or quantitatively determining in a sample an NO synthase of the invention, which method comprises
(a) contacting the sample with an antibody of the invention; and
(b) detecting or quantitatively determining the binding of the antibody.
A preferred method for detecting or quantitatively determining an NO synthase is Western blotting. Such a method can comprise the steps of
(i) subjecting a sample containing a target NO synthase to gel electrophoresis to separate the proteins in the sample;
(ii) transferring the separated proteins onto a solid support (e.g. a nitrocellulose support) by blotting; and
(iii) allowing an antibody according to the invention which has been labelled to bind to the target NO synthase.
Preferred methods of quantitative determination are ELISA (enzyme-linked immunoassay) methods such as a non- competitive ELISA methods. Typically, an ELISA method comprises the steps of
(i) immobilising on a solid support an unlabelled antibody according to the invention;
(ii) adding a sample containing the target NO synthase such that the NO synthase is captured by the unlabelled antibody;
(iii) adding an antibody according to the invention which has been labelled; and
(iv) quantitatively determining the amount of bound labelled antibody.
An antibody of the invention may be employed histologically for in situ detection of an NO synthase, e.g. by immunofluorescence or immunoelectron micropsy. In situ detection may be accomplished by removing a histological specimen from a patient, and allowing a labelled antibody to bind to the specimen. Through use of such a procedure, it is possible to determine not only the presence of an NO synthase but also its distribution.
An antibody of the invention may be used to purify a target NO synthase. Conventional methods of purifying an antigen using an antibody may be used. Such methods include immunoprecipitation and immunoaffinity column methods. In an immunoaffinity column method, an antibody in accordance with the invention is coupled to the inert matrix of the column and a sample containing the target NO synthase is passed down the column, such that the target NO synthase is retained. The NO synthase is then eluted.
The sample containing the target NO synthase used in the detection, determination and purification methods may be a tissue specimen, a tissue extract or a cell extract from a patient suffering from a disease associated with NO synthase, such as a disease listed above. Alternatively, the sample may be one produced as a result of recombinant DNA procedures, e.g. a vector or an extract of host cells.
An NO synthase of the invention is useful for screening for substrates which inhibit or stimulate the enzyme. The invention includes a method for identifying a substrate which inhibits or stimulates the NO synthase, which method comprises
(a) incubating the NO synthase with the substrate;
(b) measuring the activity of the NO synthase; and
(c) comparing the activity measured in (b) above with the activity of the NO synthase in the absence of the substrate.
For example, the activity of a substrate as an inhibitor or stimulator of the NO synthase of the present invention can be determined by an assay in which activated chondrocytes are incubated with the substrate, and NO synthase activity recorded using a dual wavelength spectrophotometer, reading at 401 and 421.
The invention also extends to substrates identified by the use of a screen hereinbefore described. Preferably the substrate is a chemical molecule of relatively low molecular weight, for example, less than about 1000. Examples of suitable classes of molecule include arginine analogues and isothiourea derivatives. Alternatively, the substrate can be a macromolecule, for example an antibody.
The invention also includes an enzyme-substrate complex which comprises an NO synthase as described herein and a substrate capable of inhibiting or stimulating the activity of the NO synthase. The enzyme-substrate complex optionally exists in an ≤x. vivo situation.
A substrate which inhibits or stimulates the NO synthase enzyme is of utility in medical therapy. Inhibition of the inducible NO synthase may have many clinical utilities, for example in the treatment of septic shock and in particular in the treatment of hypotension assosiated therewith, in therapy with cytokines such as TNF, IL-1 and IL-2 or therapy with cytokine-inducing agents, for example 5, 6-dimethylxanthenone acetic acid, as an adjuvant to short term immunosuppression in transplant therapy, in patients suffering from inflammatory conditions in which an excess of NO contributes to the pathophysiology of the condition, for example adult respiratory distress syndrome and myocarditis, and in autoimmune and/or inflammatory conditions such as arthritis and rheumatoid arthritis. Inhibition of the NO synthase enzyme may also be of use in the treatment of cerebral ischemia, CNS trauma, epilepsy, AIDS dementia, chronic neurodegenerative disease and chronic pain, and conditions in which non-adrenergic non- cholinergic nerve may be implicated such as priapism, obesity and hyperphagia. On the other hand, stimulation of the inducible NO synthase would lead to increased NO levels in the body and may be of use in treating parasitic and/or viral diseases, and killing tumour cells.
There is also provided within the scope of the present invention a pharmaceutical formulation which comprises one or more of a substrate identified using the present invention, an NO synthase as described herein, or an antibody of the present invention in combination with a pharmaceutically acceptable carrier or diluent therefor, and optionally one or more further therapeutic agents.
Formulations comprising a substrate, include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular) , rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient. Formulations comprising an NO synthase as described herein, or an antibody are those suitable for parenteral administration. All formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association a substrate, an NO synthase as described herein, or an antibody ("active ingredient") with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation. Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.
Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example, saline, water-for-injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
Formulations for rectal administration may be presented as a suppository with the usual carriers such as cocoa butter or polyethylene glycol.
Formulations for topical administration in the mouth, for example buccally or sublingually, include lozenges comprising the active ingredient in a flavoured basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia.
Preferred unit dosage formulations are those containing an effective dose, as hereinbelow recited, or an appropriate fraction thereof, of the active ingredient.
It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
The substrates are preferably administered orally or via injection at a dose of from 0.1 to 500mg/kg per day. The dose range for adult humans is generally from 5mg to 35g/day and preferably 5mg to 2g/day. Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of compound of the invention which is effective at such dosage or as a multiple of the same, for instance, units containing 5mg to 500mg, usually around lOmg to 200mg.
The NO synthase as described herein or antibody are administered parenterally at a dose of from 1 to about 100 mg for an adult patient, preferably 1 - 10 mg, usually administered daily for a period between 1 and 30 days. A two part dosing regime may be preferable wherein 1 - 5 mg are administered for 5 - 10 days followed by 6 - 15mg for a further 5 - 10 days.
The precise amount of active ingredient administered to a patient will be the responsibility of the attendant physician. However the dose employed will depend on a number of factors, including the age and sex of the patient, the precise disorder being treated, and its severity. Also the route of administration may vary depending on the condition and its severity.
The present invention will now be described by way of example only, and is not intended to be limiting thereof.
Description of the Drawings
Figure 1 shows the results of Northern blot analysis of inducible NO synthase specific mRNA from human chondrocytes. PolyA+ mRNA (0.25 μg) , extracted from induced and uninduced cells, was electrophoresed through a formaldehyde-agarose gel and transferred to a nylon membrane. The blot was hybridized with a full-length cDNA probe labelled with digoxigenin and washed under high stringency conditions. A positively hybridizing band at 4.4 kb) is apparent only in track 2 (induced) . Track 1 was loaded with the same amount of polyA+ mRNA from uninduced cells and shows no positively hybridizing band. The positions of molecular mass markers are indicated.
Figure 2 shows the results of expression of recombinant human chondrocyte inducible NO synthase in CHO cells. CHO cells were transfected with pSVL-NO containing the full-length cDNA for human iNOS, and NO synthase activity assayed as NO in the culture supernatant after (A) 24 h or (B) 96 h. Controls were parent cells alone (i.e. untransfected; closed box) and an unrelated CHO-recombinant (pSVLS; hatched box) . Only the pSVL-NO recombinant CHO cells produced significant NO in the medium (open box) and this was blocked by incubation with the NO synthase inhibitors L-N-iminoethyl- ornithine L-NIO) (100 μM) and N-guanidino-monomethyl-L-arginine (L-NMMA) (100 μM) .
MATERIALS AND METHODS
Cell culture and isolation of mRNA
Human chondrocytes were isolated and cultured. In order to induce NO synthase activity, cells were incubated with IL-lβ (1 ng/ml) for 24 h. The methods of culture and induction used were analogous to those described in relation to rabbit chondrocytes by Stadler fit al. (1991) J. Immunol 147, 3915-3920 and Palmer ≤t al. (1992) Biochem. Biophys. Res. Commun. 188, 209-215. Cells were harvested with trypsin, washed with growth medium, pelleted and frozen at -70°C. PolyA+ mRNA was extracted with a Micro Fast-Track kit (Trade Name, Invitrogen) from chondrocytes (l-2xlOε cells) incubated for 24 h with or without IL-lβ (1 ng/ml) . Typically 1-2 μg polyA+ mRNA was purified from lxlO6 cells.
The murine macrophage cell line J774 was cultured and induced to express NO synthase with interferon γ and lipopolysaccharide from Escherichia £θJLi strain 026.B6 as described previously (Cunha fit al (1993) J. Immunol 150, 1-6. PolyA+ mRNA was extracted as described above.
Dihydrofolate reductase" (DHFR')CHO cells were maintained in 75 cm flasks in Dulbecco's MEM (Trade Name, Gibco) , 10% foetal calf serum (FCS) , 1 mM L-glutamine, non essential amino acids, antibiotics, 100 μM hypoxanthine and 16 μm thymidine. pSVL transfected cells were cultured in the absence of hypoxanthine and thymidine, but in the presence of dialysed FCS and 100 μM methotrexate. For experimental purposes, cells were trypsinised from the flasks, washed once in phosphate buffered saline (PBS) and plated at 106 cells/well in 12 well plates in 3 ml of appropriate culture medium. L-N- iminoethyl-ornithine (L-NIO) or N-guanidino-monomethyl-L- arginine (L-NMMA) was added to some cultures to a final concentration of 100 μM. All cultures were then incubated at 37°C in a humidified 5% C02 atmosphere. Samples (100 μl) were removed from triplicate cultures at 24 h intervals and stored at 4°C before determination of NO by chemiluminescence (Palmer fit al. (1987), Nature 327, 524-526)
Identification of inos by reverse transcriptase- polymeraae chain reaction (RT-PCR) and construction of a cDNA library
The primers BB3 : 5 ' -CGGGATCCGGNACNGGNATHGCNCCNTT-3 '
(SEQ ID NO: 3) and BB4 : 5-GCGAATTCNCCRCANACRTADATRTG-3 • (SEQ ID NO: 4) were used to amplify random primed cDNA generated from human induced and uninduced chondrocyte polyA+ mRNA by the polymerase chain reaction (PCR) using a Gene Amp RT-PCR kit
(Trade Name, Perkin-Elmer Cetus) following the manufacturers recommended procedures. The following conditions were used: denaturation 96°C, 35s; anneal 55°C, 2 min; and extension 72°C, 3 min for 30 cycles. For a reaction volume of 100 μl, 50 ng of polyA+ mRNA was used with 50 ng of each primer. PCR products were digested with EcoRI-BamHI, resolved by agarose gel electrophoresis, purified and ligated into EcoRI-BamHI digested Bluescript pBS SKII+ (Stratagene) by standard methods (Sambrook fit al- (1989) Molecular cloning: A laboratory manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY) .
RT-PCR was carried out on polyA+ mRNA extracted from induced J774 cells using oligonucleotide primers derived from, the RAW 264.7 sequence (Lyons fit al. (1992) J. Biol. Chem. 267 6370-6374; Xie fit al- (1992) Science 256, 225-228; and Lowenstein fit al. (1992) Proc. Natl. Acad. Sci. USA 89, 6711- 6715) . The primers, AL14 : 5 ' -ACGGAGAAGCTTAGATCTGGAGCAGAAGTG-3 ' (SEQ ID NO: 5) and AL15: 5 ' -CTGCAGGTTGGACCACTGGATCCTGCCGAT-3 ' (SEQ ID NO: 6) generated a 630 bp band corresponding to the 5- end of the gene. PCR products were digested with Hindlll and BamHI purified and cloned into Hindlll-BairiHI digested Bluescript pBS SKII+ (Sambrook fit al- • supra) .
PolyA* mRNA (1.5 μg) isolated from chondrocytes activated with IL-lβ (1 ng/ml for 24 h) was used to generate a cDNA library in the bacteriophage lambda ZapII (Stratagene) . Both random and oligo-dT primers were used in the cDNA synthesis and 5xl05 independent recombinant phage were generated. Phage were amplified once, and 106 plaques plated out and screened (in duplicate) using standard techniques (Sambrook fit al- . supra) with the 630 bp fragment from the murine inducible inos gene labelled with [α32P] .
Hybridization and DNA sequencing
Blot and plaque hybridizations were carried out on GeneScreen Plus hybridization membranes (Trade Name, DuPont) . Northern blot analysis was carried out using digoxigenin labelled probes (Boehringer Mannheim) after electrophoresis and transfer of mRNA from denaturing formaldehyde-agarose gels (Sambrook ≤t al/ supra) .
Recombinant DNA was sequenced using double standard DNA as template (Stephen fit al (1991) Nucleic Acids Res. 24, 7463-7464) . An overlapping series of deletions was made in template DNA (Henikoff (1984) Gene 28, 351-359 using the exonuclease III kit (Pharmacia) . Sequencing was carried out using universal primer, [α35S] dATP and wedge gels (Sanger fit al (1983) Proc. Natl. Acad. Sci. USA 74, 5463-5467) . Clones were sequenced with modified T7 DNA polymerase (Tabor and Richardson (1987) Proc. Natl. Acad. Sci. USA 84, 4767-4771) . To resolve compression artifacts (Mizusawa fit al. (1986) Nucleic Acids Res. 14, 1319-1324) some clones were sequenced with 7-deaza-2-dGTP (Pharmacia) . Gaps in the sequence were filled in using synthetic oligonucleotides made on a Milligen 7500 DNA synthesizer (Trade Name, Millipore) as specific primers (Charles fit al (1986) Nucleic Acids. Res, 14, 2201- 2213) .
Expression of a stable CHO cell line expressing NOS DHFR" CHO cells were co-transfected with 10 μg of the full-length cDNA for the human inducible NO synthase, pSVL-NO, cloned as an Xbal fragment into the vector pSVL (Pharmacia, UK) and with 1 μg of the DHFR encoding plasmid pRDN2 (Dr. N. Sharp, Wellcome Research Laboratories, Beckenham, Kent) . Cells were seeded at 106 per 100 cm petri dish and individual recombinants cloned by dilution cloning. Individual clones were assayed for the ability to increase the N02- concentration in growth medium. One cell line, CHO-INOS-20, expressing the highest levels of inducible NO synthase was selected for further study.
Cloning of an inducible human nos gene The strategy used to clone the human chondrocyte inducible NO synthase cDNA was based on the finding that significant levels of NO synthase activity can be induced in these cells by IL-lβ. Northern blotting showed the presence of a 4.4 kb NOS-specific band in mRNA extracted from induced cells that was absent in uninduced cells (Fig. 1) . By using RT-PCR and degenerate oligonucleotide primers, a 350 bp fragment of the rabbit chondrocyte iNOS cDNA was cloned and sequenced which had greater than 90% identity with the murine inducible NO synthase sequence over this region. In order to confirm that the human chondrocyte induction was producing a similar iNOS mRNA to that induced in rabbit chondrocytes, RT-PCR was carried out using the primer set BB3 and BB4. PolyA+ mRNA (50 ng) from induced human cells was used as a template and cDNA was generated by random priming. PCR resulted in a 350 bp band which was purified, cloned and sequenced. Analysis of the sequence demonstrated that the human chondrocyte iNOS cDNA had high (>80%) identity with the murine inducible NOS cDNA over this region.
In order to clone the full-length cDNA for human iNOS, a cDNA library was constructed in lambda ZAPII using oligo dT and random primed polyA+ mRNA isolated from induced cells. To maximize the chance of finding a full-length clone a [α32P] -labelled probe was prepared form a 650 bp 5 '-fragment of the murine inducible NOS cDNA cloned from mRNA isolated from the cell line J774. This cell line has a cytokine-inducible NOS cDNA sequence that is identical to that described for the RAW 264.7 cell line (our unpublished observations) .
Screening the library with the 5' -probe resulted in the identification of several clones, one of which (pBS HSINOS) contained the full-length cDNA for iNOS. DNA sequence analysis of the 4164 bp cDNA clone showed the presence of an open reading frame capable of encoding a protein of 1153 amino acids with a calculated molecular mass of 131,213 daltons. The start site around, the ATG contains a Kozak consensus sequence (TAGAGATGG; Kozak (1991) J. Cell. Biol. 115, 887-903) . Comparison of the deduced sequence of the human inducible NO synthase with its murine counterpart shows the proteins to be highly related. The murine enzyme comprises 1144 amino acids with a calculated molecular mass of 130,556 daltons. Overall, the two proteins have 81% identity and 88% similarity as determined by the GAP align program (Trade Name, Wisconsin GCG) . Both molecules have consensus recognition sites for the co-factors FAD, FMN and NADPH and in addition have a calmodulin recognition motif, although both enzymes are Ca2+" independent.
Subcloning of full-length gene as an Xbal fragment into the expression vector pSVL generated the construct pSVL- NO. Transfection of this construct into CHO cells led to the isolation of a stable cell line expressing human inducible NO synthase under the control of a heterologous constitutive promoter (Fig. 2) . The expressed NO synthase activity was inhibited by L-NIO (100 μM) and by L-NMMA (100 μM) .
Description of the Drawings
Figure 3 SDS-PAGE of baculovirus/insect cell expressed human inducible NO synthase.
Tracks 1 and lϋ, Amersham rainbow molecular weight markers; Track 2. total cell lysate (soluble supernatant fraction;) Tracks 2.-2. are fractions from an ADP column eluted with lOmM NADPH. The arrow indicates the position of the 135kDa band corresponding to the iNOS. Samples were run on a 10% SDS-PAGE gel.
MATERIALS AND METHODS
Human inducible NO Synthase CDNA
A full-length human iNOS cDNA fragment was cloned as an Xbal fragment into the baculovirus transfer vector pVL1393 to generate pVLHINOS. This vector directs the expression of recombinant proteins under the control of the strong polyhedrin promoter. The human iNOS construct pVLMINOS was used to generate recombinant Autographa californica baculovirus using the Baculogold transfection kit (Pharmingen) .
Maintenance and infection of Spodoptera frugiperda insect cells
S. frugiperda (Sf-21) cells were maintained as stirred cultures at 27°C in TC100 medium. Roller cultures of Sf-21 cells (5 x 108 cells/800cm2 roller) were infected with human iNOS baculovirus (>108pfu/ml) at a ratio of 5pfu/cell for 24 hours at 27°C.
Preparation of NO Synthase
Cytosol preparations containing iNOS were prepared from 2 x 109 cells as described below. Briefly, the S. frugiperda cell pellet was harvested and washed in a buffer containing 0.1M Hepes pH7.4, 1.OmM dithiothreitol. Cells were resuspended (108/ml) in the same buffer and lysed by 3 freeze- thaw cycles. The resulting lysate was centrifuged at 100,000g for 30 min, and the supernatant mixed at 4°C for 45 mins with one ml of 2 '-5' ADP sepharose-4B (Pharmacia), (Charles fit al .. Biochem. Biophys. Res. Commun., 196, 1481-1489) . Following washing, NO synthase activity was eluted from the ADP sepharose with lOmM NADPH (reduced nicotinamide adenine dinuleotide phosphate) . Insect cell-derived protein samples wee resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (Charles fit al. , Infect. Immun. , 59, 1627-1632) .
NO sythase activity was measured spectrophotometrically as described previously (Palmer et al.. Biochem. Biophys. Res. Commun., 188, 209-215 and Feelisch fit al. , Eur. J Pharmac, 139, 19-30) . In some experiments the effects of altering the arginine concentrations were investigated as was the inhibition of NO synthase with L-NMMA (NG-monomethyl-L-arginine) . The effects of calcium chelation with EGTA (ethylene glycol bis- (β-aminoethylether) N^N-^N1- tetra acetic acid) and the addition of mammalian calmodulin (bovine, from Sigma) were also determined.
A cDNA clone encoding human inducible NO synthase has been isolated from a λZAPII cDNA library and cloned into the baculovirus expression vector pVL1393 as an Xbal fragment. Transfection into S. frugiperda (Sf-21) cells results in the expression of NO synthase activity that can be isolated by a freeze-thaw procedure. Fig 3 shows 10% SDS-PAGE gel showing the NADPH elution profile of NO synthase from an ADP sepharose column. Track 2 shows the S. frugiperda iNOS cell lysate following high speed centrifugation. No clear band is seen corresponding to recombinant iNOS indicating that the NO synthase is not expressed at high level. This contrasts with the expression of the neuronal forms of NO synthase that can be expressed at high (15-20% total cell protein) levels in insect cells. Tracks 3-9 show the NADPH elution profile. A major band at 135kDa corresponds to the human iNOS. Lower molecular weight bands seen on the gel cross-react with polyclonal antibody against murine iNOS in western blot experiments (data not shown) suggesting that they represent break-down products of the full-length iNOS.
Kinetic studies on recombinant iNOS shows that it has similar characteristics as its native counterpart, with a similar Km for L-arginine (Table 1) . The Vmax measurements are made on crude protein and are solely a measure of enzyme expression, demonstrating that more iNOS is being produced in the baculovirus system than the induced mammalian cells. Inhibition studies using the NO synthase inhibitor L-NMMA demonstrated that recombinant and native iNOS have similar IC50 values at 30μM L-arginine, with a Ki for L-NMMA of 15μM. Although chelation of free calcium to a very low concentration by the addition of EGTA (ImM) caused modest inhibition of the recombinant iNOS (59 ± 8.3% inhibition, n=4) this was reversed by the addition of mammalian calmodulin (500μ/ml) . Thus, in the presence of mammalian calmodulin the recombinant iNOS was inhibited less than 20% by removal of calcium (18 ± 8.9% inhibition, n=4) , consistent with the behaviour of native iNOS (Palmer ≤t al. - (1993) Biochem. Biophys. Res. Commun., 193, 398-405; Radomski fit al (1991) Cancer Res., 51, 6073-6078; Stuehr fit al- , (1992) Adv. Enzymol. , 65, 287-346) .
Table 1 :Summary of the characteristics of recombinant human iNOS compared with its native counterpart. The native iNOS was fneasured from IL- 1 induced human chondrocytes and megakaryocytes (Meg- 01 ) and a human adenocarcinoma cell -line SW480 .
Properties of Expressed Recombinant Human iNOS
Recombinant Human Native Human iNOS iNOS
220 (IL-1 treated
Vmax chondrocytes ) (pmol/min per mg) 430 ± 150 180 (SW480 cells)
3 (IL-1 treated Meg-01 cells)
Km for L-Arg (μM) 4 . 0 ± 0 .38 4 (Meg- 01)
IC50 for L-NMMA 12 (chondrocytes) (μM at 30μM L-Arg) 13 ± 2.0 19 (Meg-01)
(2) INFORMATION FOR SEQ ID Nθ:l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4164 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS : double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens (G) CELL TYPE: chondrocyte
(A) NAME/KEY: CDS
(B) LOCATION: 226..3687
(xi) SEQUENCE DESCRIPTION: SEQ ID Nθ:l:
AGAGAACTCA GCCTCATTCC TGCTTTAAAA TCTCTCGGCC ACCTTTGATG AGGGGACTGG 60
GCAGTTCTAG ACAGTCCCGA AGTTCTCAAG GCACAGGTCT CTTCCTGGTT TGACTGTCCT 120
TACCCCGGGG AGGCAGTGCA GCCAGCTGCA AGCCCCACAG TGAAGAACAT CTGAGCTCAA 180
SUBSTITUTESHEET.(RULE26) ATCCAGATAA GTGACATAAG TGACCTGCTT TGTAAAGCCA TAGAG ATG GCC TGT 234
Met Ala Cys
CCT TGG AAA TTT CTG TTC AAG ACC AAA TTC CAC CAG TAT GCA ATG AAT 282 Pro Trp Lys Phe Leu Phe Lys Thr Lys Phe His Gin Tyr Ala Met Asn 5 10 15
GGG GAA AAA GAC ATC AAC AAC AAT GTG GAG AAA GCC CCC TGT GCC ACC 330 Gly Glu Lys Asp He Asn Asn Asn Val Glu Lys Ala Pro Cys Ala Thr 20 25 30 35
TCC AGT CCA GTG ACA CAG GAT GAC CTT CAG TAT CAC AAC CTC AGC AAG 378 Ser Ser Pro Val Thr Gin Asp Asp Leu Gin Tyr His Asn Leu Ser Lys 40 45 50
CAG CAG AAT GAG TCC CCG CAG CCC CTC GTG GAG ACG GGA AAG AAG TCT 426 Gin Gin Asn Glu Ser Pro Gin Pro Leu Val Glu Thr Gly Lys Lys Ser 55 60 65
CCA GAA TCT CTG GTC AAG CTG GAT GCA ACC CCA TTG TCC TCC CCA CGG 474 Pro Glu Ser Leu Val Lys Leu Asp Ala Thr Pro Leu Ser Ser Pro Arg 70 75 80
CAT GTG AGG ATC AAA AAC TGG GGC AGC GGG ATG ACT TTC CAA GAC ACA 522 His Val Arg He Lys Asn Trp Gly Ser Gly Met Thr Phe Gin Asp Thr 85 90 95
CTT CAC CAT AAG GCC AAA GGG ATT TTA ACT TGC AGG TCC AAA TCT TGC 570
Leu His His Lys Ala Lys Gly He Leu Thr Cys Arg Ser Lys Ser Cys 100 105 110 115
CTG GGG TCC ATT ATG ACT CCC AAA AGT TTG ACC AGA GGA CCC AGG GAC 618
Leu Gly Ser He Met Thr Pro Lys Ser Leu Thr Arg Gly Pro Arg Asp 120 125 130
AAG CCT ACC CCT CCA GAT GAG CTT CTA CCT CAA GCT ATC GAA TTT GTC 666
Lys Pro Thr Pro Pro Asp Glu Leu Leu Pro Gin Ala He Glu Phe Val
135 140 145
AAC CAA TAT TAC GGC TCC TTC AAA GAG GCA AAA ATA GAG GAA CAT CTG 714
Asn Gin Tyr Tyr Gly Ser Phe Lys Glu Ala Lys He Glu Glu His Leu 150 155 160
GCC AGG GTG GAA GCG GTA ACA AAG GAG ATA GAA ACA ACA GGA ACC TAC 762
Ala Arg Val Glu Ala Val Thr Lys Glu He Glu Thr Thr Gly Thr Tyr 165 170 175
CAA CTG ACG GGA GAT GAG CTC ATC TTC GCC ACC AAG CAG GCC TGG CGC 810
Gin Leu Thr Gly Asp Glu Leu He Phe Ala Thr Lys Gin Ala Trp Arg 180 185 190 195
AAT GCC CCA CGC TGC ATT GGG AGG ATC CAG TGG TCC AAC CTG CAG GTC 858
Asn Ala Pro Arg Cys He Gly Arg He Gin Trp Ser Asn Leu Gin Val 200 205 210
TTC GAT GCC CGC AGC TGT TCC ACT GCC CGG GAA ATG TTT GAA CAC ATC 906 Phe Asp Ala Arg Ser Cys Ser Thr Ala Arg Glu Met Phe Glu His He 215 220 225 TGC AGA CAC GTG CGT TAC TCC ACC AAC AAT GGC AAC ATC AGG TCG GCC 954
Cys Arg His Val Arg Tyr Ser Thr Asn Asn Gly Asn He Arg Ser Ala 230 235 240
ATC ACC GTG TTC CCC CAG CGG AGT GAT GGC AAG CAC GAC TTC CGG GTG 1002
He Thr Val Phe Pro Gin Arg Ser Asp Gly Lys His Asp Phe Arg Val 245 250 255
TGG AAT GCT CAG CTC ATC CGC TAT GCT GGC TAC CAG ATG CCA GAT GGC 1050
Trp Asn Ala Gin Leu He Arg Tyr Ala Gly Tyr Gin Met Pro Asp Gly
260 265 270 275
AGC ATC AGA GGG GAC CCT GCC AAC GTG GAA TTC ACT CAG CTG TGC ATC 1098
Ser He Arg Gly Asp Pro Ala Asn Val Glu Phe Thr Gin Leu Cys He 280 285 290
GAC CTG GGC TGG AAG CCC AAG TAC GGC CGC TTC GAT GTG GTC CCC CTG 1146
Asp Leu Gly Trp Lys Pro Lys Tyr Gly Arg Phe Asp Val Val Pro Leu 295 300 305
GTC CTG CAG GCC AAT GGC CGT GAC CCT GAG CTC TTC GAA ATC CCA CCT 1194 Val Leu Gin Ala Asn Gly Arg Asp Pro Glu Leu Phe Glu He Pro Pro 310 315 320
GAC CTT GTG CTT GAG GTG GCC ATG GAA CAT CCC AAA TAC GAG TGG TTT 1242 Asp Leu Val Leu Glu Val Ala Met Glu His Pro Lys Tyr Glu Trp Phe 325 330 335
CGG GAA CTG GAG CTA AAG TGG TAC GCC CTG CCT GCA GTG GCC AAC ATG 1290 Arg Glu Leu Glu Leu Lys Trp Tyr Ala Leu Pro Ala Val Ala Asn Met 340 345 350 355
CTG CTT GAG GTG GGC GGC CTG GAG TTC CCA GGG TGC CCC TTC AAT GGC 1338 Leu Leu Glu Val Gly Gly Leu Glu Phe Pro Gly Cys Pro Phe Asn Gly 360 365 370
TGG TAC ATG GGC ACA GAG ATC GGA GTC CGG GAC TTC TGT GAC GTC CAG 1386 Trp Tyr Met Gly Thr Glu He Gly Val Arg Asp Phe Cys Asp Val Gin 375 380 385
CGC TAC AAC ATC CTG GAG GAA GTG GGC AGG AGA ATG GGC CTG GAA ACG 1434 Arg Tyr Asn He Leu Glu Glu Val Gly Arg Arg Met Gly Leu Glu Thr 390 395 400
CAC AAG CTG GCC TCG CTC TGG AAA GAC CAG GCT GTC GTT GAG ATC AAC 1482 His Lys Leu Ala Ser Leu Trp Lys Asp Gin Ala Val Val Glu He Asn 405 410 415
ATT GCT GTG CTC CAT AGT TTC CAG AAG CAG AAT GTG ACC ATC ATG GAC 1530 He Ala Val Leu His Ser Phe Gin Lys Gin Asn Val Thr He Met Asp 420 425 430 435
CAC CAC TCG GCT GCA GAA TCC TTC ATG AAG TAC ATG CAG AAT GAA TAC 1578 His His Ser Ala Ala Glu Ser Phe Met Lys Tyr Met Gin Asn Glu Tyr 440 445 450
CGG TCC CGT GGG GGC TGC CCG GCA GAC TGG ATT TGG CTG GTC CCT CCC 1626 Arg Ser Arg Gly Gly Cys Pro Ala Asp Trp He Trp Leu Val Pro Pro 455 460 465 ATG' TCT GGG AGC ATC ACC CCC GTG TTT CAC CAG GAG ATG CTG AAC TAC 1674 Met Ser Gly Ser He Thr Pro Val Phe His Gin Glu Met Leu Asn Tyr 470 475 480
GTC CTG TCC CCT TTC TAC TAC TAT CAG GTA GAG GCC TGG AAA ACC CAT 1722 Val Leu Ser Pro Phe Tyr Tyr Tyr Gin Val Glu Ala Trp Lys Thr His 485 490 495
GTC TGG CAG GAC GAG AAG CGG AGA CCC AAG AGA AGA GAG ATT CCA TTG 1770 Val Trp Gin Asp Glu Lys Arg Arg Pro Lys Arg Arg Glu He Pro Leu 500 505 510 515
AAA GTC TTG GTC AAA GCT GTG CTC TTT GCC TGT ATG CTG ATG CGC AAG 1818 Lys Val Leu Val Lys Ala Val Leu Phe Ala Cys Met Leu Met Arg Lys 520 525 530
ACA ATG GCG TCC CGA GTC AGA GTC ACC ATC CTC TTT GCG ACA GAG ACA 1866 Thr Met Ala Ser Arg Val Arg Val Thr He Leu Phe Ala Thr Glu Thr 535 540 545
GGA AAA TCA GAG GCG CTG GCC TGG GAC CTG GGG GCC TTA TTC AGC TGT 1914 Gly Lys Ser Glu Ala Leu Ala Trp Asp Leu Gly Ala Leu Phe Ser Cys 550 555 560
GCC TTC AAC CCC AAG GTT GTC TGC ATG GAT AAG TAC AGG CTG AGC TGC 1962 Ala Phe Asn Pro Lys Val Val Cys Met Asp Lys Tyr Arg Leu Ser Cys 565 570 575
CTG GAG GAG GAA CGG CTG CTG TTG GTG GTG ACC AGT ACG TTT GGC AAT 2010 Leu Glu Glu Glu Arg Leu Leu Leu Val Val Thr Ser Thr Phe Gly Asn 580 585 590 595
GGA GAC TGC CCT GGC AAT GGA GAG AAA CTG AAG AAA TCG CTC TTC ATG 2058 Gly Asp Cys Pro Gly Asn Gly Glu Lys Leu Lys Lys Ser Leu Phe Met 600 605 610
CTG AAA GAG CTC AAC AAC AAA TTC AGG TAC GCT GTG TTT GGC CTC GGC 2106 Leu Lys Glu Leu Asn Asn Lys Phe Arg Tyr Ala Val Phe Gly Leu Gly 615 620 625
TCC AGC ATG TAC CCT CGG TTC TGC GCC TTT GCT CAT GAC ATT GAT CAG 2154 Ser Ser Met Tyr Pro Arg Phe Cys Ala Phe Ala His Asp He Asp Gin 630 635 640
AAG CTG TCC CAC CTG GGG GCC TCT CAG CTC ACC CCG ATG GGA GAA GGG 2202 Lys Leu Ser His Leu Gly Ala Ser Gin Leu Thr Pro Met Gly Glu Gly 645 650 655
GAT GAG CTC AGT GGG CAG GAG GAC GCC TTC CGC AGC TGG GCC GTG CAA 2250 Asp Glu Leu Ser Gly Gin Glu Asp Ala Phe Arg Ser Trp Ala Val Gin 660 665 670 675
ACC TTC AAG GCA GCC TGT GAG ACG TTT GAT GTC CGA GGC AAA CAG CAC 2298 Thr Phe Lys Ala Ala Cys Glu Thr Phe Asp Val Arg Gly Lys Gin His 680 685 690
ATT CAG ATC CCC AAG CTC TAC ACC TCC AAT GTG ACC TGG GAC CCG CAC 2346 He Gin He Pro Lys Leu Tyr Thr Ser Asn Val Thr Trp Asp Pro His 695 700 705 CAC TAC AGG CTC GTG CAG GAC TCA CAG CCT TTG GAC CTC AGC AAA GCC 2394 His Tyr Arg Leu Val Gin Asp Ser Gin Pro Leu Asp Leu Ser Lys Ala 710 715 720
CTC AGC AGC ATG CAT GCC AAG AAC GTG TTC ACC ATG AGG CTC AAA TCT 2442 Leu Ser Ser Met His Ala Lys Asn Val Phe Thr Met Arg Leu Lys Ser 725 730 735
CGG CAG AAT CTA CAA AGT CCG ACA TCC AGC CGT GCC ACC ATC CTG GTG 2490 Arg Gin Asn Leu Gin Ser Pro Thr Ser Ser Arg Ala Thr He Leu Val 740 745 750 755
GAA CTC TCC TGT GAG GAT GGC CAA GGC CTG AAC TAC CTG CCG GGG GAG 2538
Glu Leu Ser Cys Glu Asp Gly Gin Gly Leu Asn Tyr Leu Pro Gly Glu 760 765 770
CAC CTT GGG GTT TGC CCA GGC AAC CAG CCG GCC CTG GTC CAA GGT ATC 2586
His Leu Gly Val Cys Pro Gly Asn Gin Pro Ala Leu Val Gin Gly He
775 780 785
CTG GAG CGA GTG GTG GAT GGC CCC ACA CCC CAC CAG ACA GTG CGC CTG 2634
Leu Glu Arg Val Val Asp Gly Pro Thr Pro His Gin Thr Val Arg Leu 790 795 800
GAG GCC CTG GAT GAG AGT GGC AGC TAC TGG GTC AGT GAC AAG AGG CTG 2682
Glu Ala Leu Asp Glu Ser Gly Ser Tyr Trp Val Ser Asp Lys Arg Leu 805 810 815
CCC CCC TGC TCA CTC AGC CAG GCC CTC ACC TAC TTC CTG GAC ATC ACC 2730
Pro Pro Cys Ser Leu Ser Gin Ala Leu Thr Tyr Phe Leu Asp He Thr
820 825 830 835
ACA CCC CCA ACC CAG CTG CTG CTC CAA AAG CTG GCC CAG GTG GCC ACA 2778
Thr Pro Pro Thr Gin Leu Leu Leu Gin Lys Leu Ala Gin Val Ala Thr 840 845 850
GAA GAG CCT GAG AGA CAG AGG CTG GAG GCC CTG TGC CAG CCC TCA GAG 2826
Glu Glu Pro Glu Arg Gin Arg Leu Glu Ala Leu Cys Gin Pro Ser Glu
855 860 865
TAC AGC AAG TGG AAG TTC ACC AAC AGC CCC ACA TTC CTG GAG GTG CTA 2874
Tyr Ser Lys Trp Lys Phe Thr Asn Ser Pro Thr Phe Leu Glu Val Leu 870 875 880
GAG GAG TTC CCG TCC CTG CGG GTG TCT GCT GGC TTC CTG CTT TCC CAG 2922
Glu Glu Phe Pro Ser Leu Arg Val Ser Ala Gly Phe Leu Leu Ser Gin 885 890 895
CTC CCC ATT CTG AAG CCC AGG TTC TAC TCC ATC AGC TCC TCC CGG GAT 2970
Leu Pro He Leu Lys Pro Arg Phe Tyr Ser He Ser Ser Ser Arg Asp
900 905 910 915 CAC ACG CCC ACA GAG ATC CAC CTG ACT GTG GCC GTG GTC ACC TAC CAC 3018 His Thr Pro Thr Glu He His Leu Thr Val Ala Val Val Thr Tyr His 920 925 930
ACC CGA GAT GGC CAG GGT CCC CTG CAC CAC GGC GTC TGC AGC ACA TGG 3066 Thr Arg Asp Gly Gin Gly Pro Leu His His Gly Val Cys Ser Thr Trp 935 940 945
CTC AAC AGC CTG AAG CCC CAA GAC CCA GTG CCC TGC TTT GTG CGG AAT 3114 Leu Asn Ser Leu Lys Pro Gin Asp Pro Val Pro Cys Phe Val Arg Asn 950 955 960
GCC AGC GGC TTC CAC CTC CCC GAG GAT CCC TCC CAT CCT TGC ATC CTC 3162 Ala Ser Gly Phe His Leu Pro Glu Asp Pro Ser His Pro Cys He Leu 965 970 975
ATC GGG CCT GGC ACA GGC ATC GCG CCC TTC CGC AGT TTC TGG CAG CAA 3210 He Gly Pro Gly Thr Gly He Ala Pro Phe Arg Ser Phe Trp Gin Gin '980 985 990 995
CGG CTC CAT GAC TCC CAG CAC AAG GGA GTG CGG GGA GGC CGC ATG ACC 3258 Arg Leu His Asp Ser Gin His Lys Gly Val Arg Gly Gly Arg Met Thr 1000 1005 1010
TTG GTG TTT GGG TGC CGC CGC CCA GAT GAG GAC CAC ATC TAC CAG GAG 3306 Leu Val Phe Gly Cys Arg Arg Pro Asp Glu Asp His He Tyr Gin Glu 1015 1020 1025
GAG ATG CTG GAG ATG GCC CAG AAG GGG GTG CTG CAT GCG GTG CAC ACA 3354 Glu Met Leu Glu Met Ala Gin Lys Gly Val Leu His Ala Val His Thr 1030 1035 1040
GCC TAT TCC CGC CTG CCT GGC AAG CCC AAG GTC TAT GTT CAG GAC ATC 3402 Ala Tyr Ser Arg Leu Pro Gly Lys Pro Lys Val Tyr Val Gin Asp He 1045 1050 1055
CTG CGG CAG CAG CTG GCC AGC GAG GTG CTC CGT GTG CTC CAC AAG GAG 3450 Leu Arg Gin Gin Leu Ala Ser Glu Val Leu Arg Val Leu His Lys Glu 1060 1065 1070 1075
CCA GGC CAC CTC TAT GTT TGC GGG GAT GTG CGC ATG GCC CGG GAC GTG 3498 Pro Gly His Leu Tyr Val Cys Gly Asp Val Arg Met Ala Arg Asp Val 1080 1085 1090
GCC CAC ACC CTG AAG CAG CTG GTG GCT GCC AAG CTG AAA TTG AAT GAG 3546 Ala His Thr Leu Lys Gin Leu Val Ala Ala Lys Leu Lys Leu Asn Glu 1095 1100 1105
GAG CAG GTC GAG GAC TAT TTC TTT CAG CTC AAG AGC CAG AAG CGC TAT 3594 Glu Gin Val Glu Asp Tyr Phe Phe Gin Leu Lys Ser Gin Lys Arg Tyr 1110 1115 1120
CAC GAA GAT ATC TTT GGT GCT GTA TTT CCT TAC GAG GCG AAG AAG GAC 3642 His Glu Asp He Phe Gly Ala Val Phe Pro Tyr Glu Ala Lys Lys Asp 1125 1130 1135
AGG GTG GCG GTG CAG CCC AGC AGC CTG GAG ATG TCA GCG CTC TGAGGGCCTA 3694 Arg Val Ala Val Gin Pro Ser Ser Leu Glu Met Ser Ala Leu 1140 1145 1150 CAGGAGGGGT TAAAGCTGCC GGCACAGAAC TTAAGGATGG AGCCAGCTCT GCATTATCTG 3754
AGGTCACAGG GCCTGGGGAG ATGGAGGAAA GTGATATCCC CCAGCCTCAA GTCTTATTTC 3814
CTCAACGTTG CTCCCCATCA AGCCCTTTAC TTGACCTCCT AACAAGTAGC ACCCTGGATT 3874
GATCGGAGCC TCCTCTCTCA AACTGGGGCC TCCCTGGTCC CTTGGAGACA AAATCTTAAA 3934
TGCCAGGCCT GGCAAGTGGG TGAAAGATGG AACTTGCTGC TGAGTGCACC ACTTCAAGTG 3994
ACCACCAGGA GGTGCTATCG CACCACTGTG TATTTAACTG CCTTGTGTAC AGTTATTTAT 4054
GCCTCTGTAT TTAAAAAACT AACACCCAGT CTGTTCCCCA TGGCCACTTG GGTCTTCCCT 4114
GTATGATTCC TTGATGGAGA TATTTACATG AATTGCATTT TACTTTAATC 4164
(2) INFORMATION FOR SEQ ID Nθ:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1153 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
Met Ala Cys Pro Trp Lys Phe Leu Phe Lys Thr Lys Phe His Gin Tyr 1 5 10 15
Ala Met Asn Gly Glu Lys Asp He Asn Asn Asn Val Glu Lys Ala Pro 20 25 30
Cys Ala Thr Ser Ser Pro Val Thr Gin Asp Asp Leu Gin Tyr His Asn 35 40 45
Leu Ser Lys Gin Gin Asn Glu Ser Pro Gin Pro Leu Val Glu Thr Gly 50 55 60
Lys Lys Ser Pro Glu Ser Leu Val Lys Leu Asp Ala Thr Pro Leu Ser 65 70 75 80
Ser Pro Arg His Val Arg He Lys Asn Trp Gly Ser Gly Met Thr Phe 85 90 95
Gin Asp Thr Leu His His Lys Ala Lys Gly He Leu Thr Cys Arg Ser 100 105 110
Lys Ser Cys Leu Gly Ser He Met Thr Pro Lys Ser Leu Thr Arg Gly 115 120 125
Pro Arg Asp Lys Pro Thr Pro Pro Asp Glu Leu Leu Pro Gin Ala He 130 135 140
Glu Phe Val Asn Gin Tyr Tyr Gly Ser Phe Lys Glu Ala Lys He Glu 145 150 155 160
Glu His Leu Ala Arg Val Glu Ala Val Thr Lys Glu He Glu Thr Thr 165 170 175 Gly Thr Tyr Gin Leu Thr Gly Asp Glu Leu He Phe Ala Thr Lys Gin 180 185 190
Ala Trp Arg Asn Ala Pro Arg Cys He Gly Arg He Gin Trp Ser Asn 195 200 205
Leu Gin Val Phe Asp Ala Arg Ser Cys Ser Thr Ala Arg Glu Met Phe 210 215 220
Glu His He Cys Arg His Val Arg Tyr Ser Thr Asn Asn Gly Asn He 225 230 235 240
Arg Ser Ala He Thr Val Phe Pro Gin Arg Ser Asp Gly Lys His Asp 245 250 255
Phe Arg Val Trp Asn Ala Gin Leu He Arg Tyr Ala Gly Tyr Gin Met 260 265 270
Pro Asp Gly Ser He Arg Gly Asp Pro Ala Asn Val Glu Phe Thr Gin 275 280 285
Leu Cys He Asp Leu Gly Trp Lys Pro Lys Tyr Gly Arg Phe Asp Val 290 295 300
Val Pro Leu Val Leu Gin Ala Asn Gly Arg Asp Pro Glu Leu Phe Glu 305 310 315 320
He Pro Pro Asp Leu Val Leu Glu Val Ala Met Glu His Pro Lys Tyr 325 330 335
Glu Trp Phe Arg Glu Leu Glu Leu Lys Trp Tyr Ala Leu Pro Ala Val 340 345 350
Ala Asn Met Leu Leu Glu Val Gly Gly Leu Glu Phe Pro Gly Cys Pro 355 360 365
Phe Asn Gly Trp Tyr Met Gly Thr Glu He Gly Val Arg Asp Phe Cys 370 375 380
Asp Val Gin Arg Tyr Asn He Leu Glu Glu Val Gly Arg Arg Met Gly 385 390 395 400
Leu Glu Thr His Lys Leu Ala Ser Leu Trp Lys Asp Gin Ala Val Val 405 410 415
Glu He Asn He Ala Val Leu His Ser Phe Gin Lys Gin Asn Val Thr 420 425 430
He Met Asp His His Ser Ala Ala Glu Ser Phe Met Lys Tyr Met Gin 435 440 445
Asn Glu Tyr Arg Ser Arg Gly Gly Cys Pro Ala Asp Trp He Trp Leu 450 455 460
Val Pro Pro Met Ser Gly Ser He Thr Pro Val Phe His Gin Glu Met 465 470 475 480
Leu Asn Tyr Val Leu Ser Pro Phe Tyr Tyr Tyr Gin Val Glu Ala Trp 485 490 495
Lys Thr His Val Trp Gin Asp Glu Lys Arg Arg Pro Lys Arg Arg Glu 500 505 510 He Pro Leu Lys Val Leu Val Lys Ala Val Leu Phe Ala Cys Met Leu 515 520 525
Met Arg Lys Thr Met Ala Ser Arg Val Arg Val Thr He Leu Phe Ala 530 535 540
Thr Glu Thr Gly Lys Ser Glu Ala Leu Ala Trp Asp Leu Gly Ala Leu 545 550 555 560
Phe Ser Cys Ala Phe Asn Pro Lys Val Val Cys Met Asp Lys Tyr Arg 565 570 575
Leu Ser Cys Leu Glu Glu Glu Arg Leu Leu Leu Val Val Thr Ser Thr 580 585 590
Phe Gly Asn Gly Asp Cys Pro Gly Asn Gly Glu Lys Leu Lys Lys Ser 595 600 605
Leu Phe Met Leu Lys Glu Leu Asn Asn Lys Phe Arg Tyr Ala Val Phe 610 615 620
Gly Leu Gly Ser Ser Met Tyr Pro Arg Phe Cys Ala Phe Ala His Asp 625 630 635 640
He Asp Gin Lys Leu Ser His Leu Gly Ala Ser Gin Leu Thr Pro Met 645 650 655
Gly Glu Gly Asp Glu Leu Ser Gly Gin Glu Asp Ala Phe Arg Ser Trp 660 665 670
Ala Val Gin Thr Phe Lys Ala Ala Cys Glu Thr Phe Asp Val Arg Gly 675 680 685
Lys Gin His He Gin He Pro Lys Leu Tyr Thr Ser Asn Val Thr Trp 690 695 700
Asp Pro His His Tyr Arg Leu Val Gin Asp Ser Gin Pro Leu Asp Leu 705 710 715 720
Ser Lys Ala Leu Ser Ser Met His Ala Lys Asn Val Phe Thr Met Arg 725 730 735
Leu Lys Ser Arg Gin Asn Leu Gin Ser Pro Thr Ser Ser Arg Ala Thr 740 745 750
He Leu Val Glu Leu Ser Cys Glu Asp Gly Gin Gly Leu Asn Tyr Leu 755 760 765
Pro Gly Glu His Leu Gly Val Cys Pro Gly Asn Gin Pro Ala Leu Val 770 775 780
Gin Gly He Leu Glu Arg Val Val Asp Gly Pro Thr Pro His Gin Thr 785 790 795 800
Val Arg Leu Glu Ala Leu Asp Glu Ser Gly Ser Tyr Trp Val Ser Asp 805 810 815
Lys Arg Leu Pro Pro Cys Ser Leu Ser Gin Ala Leu Thr Tyr Phe Leu 820 825 830 Asp He Thr Thr Pro Pro Thr Gin Leu Leu Leu Gin Lys Leu Ala Gin 835 840 845
Val Ala Thr Glu Glu Pro Glu Arg Gin Arg Leu Glu Ala Leu Cys Gin 850 855 860
Pro Ser Glu Tyr Ser Lys Trp Lys Phe Thr Asn Ser Pro Thr Phe Leu 865 870 875 880
Glu Val Leu Glu Glu Phe Pro Ser Leu Arg Val Ser Ala Gly Phe Leu 885 890 895
Leu Ser Gin Leu Pro He Leu Lys Pro Arg Phe Tyr Ser He Ser Ser 900 905 910
Ser Arg Asp His Thr Pro Thr Glu He His Leu Thr Val Ala Val Val 915 920 925
Thr Tyr His Thr Arg Asp Gly Gin Gly Pro Leu His His Gly Val Cys 930 935 940
Ser Thr Trp Leu Asn Ser Leu Lys Pro Gin Asp Pro Val Pro Cys Phe 945 950 955 960
Val Arg Asn Ala Ser Gly Phe His Leu Pro Glu Asp Pro Ser His Pro 965 970 975
Cys He Leu He Gly Pro Gly Thr Gly He Ala Pro Phe Arg Ser Phe 980 985 990
Trp Gin Gin Arg Leu His Asp Ser Gin His Lys Gly Val Arg Gly Gly 995 1000 1005
Arg Met Thr Leu Val Phe Gly Cys Arg Arg Pro Asp Glu Asp His He 1010 1015 1020
Tyr Gin Glu Glu Met Leu Glu Met Ala Gin Lys Gly Val Leu His Ala 1025 1030 1035 1040
Val His Thr Ala Tyr Ser Arg Leu Pro Gly Lys Pro Lys Val Tyr Val 1045 1050 1055
Gin Asp He Leu Arg Gin Gin Leu Ala Ser Glu Val Leu Arg Val Leu 1060 1065 1070
His Lys Glu Pro Gly His Leu Tyr Val Cys Gly Asp Val Arg Met Ala 1075 1080 1085
Arg Asp Val Ala His Thr Leu Lys Gin Leu Val Ala Ala Lys Leu Lys 1090 1095 1100
Leu Asn Glu Glu Gin Val Glu Asp Tyr Phe Phe Gin Leu Lys Ser Gin 1105 1110 1115 1120
Lys Arg Tyr His Glu Asp He Phe Gly Ala Val Phe Pro Tyr Glu Ala 1125 1130 1135
Lys Lys Asp Arg Val Ala Val Gin Pro Ser Ser Leu Glu Met Ser Ala 1140 1145 1150
Leu (2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: CGGGATCCGG NACNGGNATH GCNCCNTT 28
(2) INFORMATION FOR SEQ ID Nθ:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID Nθ:4: GCGAATTCNC CRCANACRTA DATRTG 26
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: ACGGAGAAGC TTAGATCTGG AGCAGAAGTG 30
(2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: CTGCAGGTTG GACCACTGGA TCCTGCCGAT 30
|1||*||CHARLES ET AL.: "Cloning, characterization and expression of a cDNA encoding an inducible nitric oxide synthase from the human chondrocyte", PROC. NATL ACAD. SCI., vol. 90, December 1993 (1993-12-01), pages 11419 - 11423|
|2||*||LOWENSTEIN ET AL.: "Cloned and expressed macrophage nitric oxide synthase contrasts with the brain enzyme", PROC. NATL ACAD. SCI., vol. 89, 1 August 1992 (1992-08-01), pages 6711 - 6715|
|3||*||LYONS ET AL.: "Molecular cloning and functional expression of an inducible nitric oxide synthase from a murine macrophage cell line", J. BIOL. CHEM., vol. 267, no. 9, 25 March 1992 (1992-03-25), pages 6370 - 6374|
|4||*||NUNOKAWA ET AL.: "Cloning of inducible nitric oxide synthase in rat vascular smooth muscle cells", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 191, no. 1, 26 February 1993 (1993-02-26), pages 89 - 94|
|5||*||REDICKE ET AL.: "Human articular chondrocytes induced by proinflammatory cytokines are the major intraarticular source of nitric oxide (NO) and NO mediates the IL-1 induction of cGMP", ARTHRIT. RHEUMAT., vol. 36, no. SUP9, September 1993 (1993-09-01), pages S189|
|Patente citante||Fecha de presentación||Fecha de publicación||Solicitante||Título|
|WO1996039858A1 *||3 Jun 1996||19 Dic 1996||Merck & Co., Inc.||Monospecific antibodies and methods using them|
|WO1996040785A1 *||3 Jun 1996||19 Dic 1996||Merck & Co., Inc.||Monospecific antibodies and methods using them|
|WO1996041885A1 *||6 Jun 1996||27 Dic 1996||Schering Corporation||Expression of human inducible nitric oxide synthase|
|WO2000066725A1 *||3 May 2000||9 Nov 2000||Aventis Pharma S.A.||Use of inducible no-synthase antisense oligonucleotides for preventing and treating cerebral ischemia|
|WO2001066791A1 *||9 Mar 2001||13 Sep 2001||Fujisawa Pharmaceutical Co., Ltd.||Method of screening inducible nitric oxide synthase activation inhibitor|
|EP0769903A1 *||20 Jun 1995||2 May 1997||University Of Pittsburgh Of The Commonwealth System Of Higher Education||Inducible nitric oxide synthase gene for treatment of disease|
|EP0769903A4 *||20 Jun 1995||27 Oct 1999||Univ Pittsburgh||Inducible nitric oxide synthase gene for treatment of disease|
|EP0864648A1 *||18 Sep 1997||16 Sep 1998||Suntory Limited||Method for screening compounds regulating the expression of human-inducible nitric oxide synthase|
|EP0864648A4 *||18 Sep 1997||30 Oct 2002||Suntory Ltd||Method for screening compounds regulating the expression of human-inducible nitric oxide synthase|
|EP1250157A1 *||16 Ene 2001||23 Oct 2002||Isis Pharmaceuticals, Inc.||Antisense modulation of inducible nitric oxide synthase expression|
|EP1250157A4 *||16 Ene 2001||29 Dic 2004||Isis Pharmaceuticals Inc||Antisense modulation of inducible nitric oxide synthase expression|
|US5744340 *||9 Jun 1995||28 Abr 1998||Schering Corporation||Expression of human inducible nitric oxide synthase|
|US5830461 *||8 Nov 1996||3 Nov 1998||University Of Pittsburgh Of The Commonwealth System Of Higher Education||Methods for promoting wound healing and treating transplant-associated vasculopathy|
|US5908842 *||8 Dic 1995||1 Jun 1999||Merck & Co., Inc.||Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase|
|US6090839 *||19 Dic 1997||18 Jul 2000||Merck & Co., Inc.||Antidiabetic agents|
|US6103230 *||2 Oct 1998||15 Ago 2000||University Of Pittsburgh Of The Commonwealth System Of Higher Education||Methods for promoting wound healing and treating transplant-associated vasculopathy|
|US6146887 *||28 Jul 1998||14 Nov 2000||Jurgen Schrader||DNA expression vectors for use in the gene therapeutic treatment of vascular disorders|
|US6149936 *||28 Jul 1998||21 Nov 2000||Joseph Schrader||DNA expression vectors for the use in the gene therapeutic treatment of vascular disorders|
|US6160000 *||19 Dic 1997||12 Dic 2000||Merck & Co., Inc.||Antidiabetic agents based on aryl and heteroarylacetic acids|
|US6531578 *||12 Abr 1996||11 Mar 2003||Robert Webber||Immunoassay method employing monoclonal antibody reactive to human iNOS|
|US7198904 *||7 Abr 1997||3 Abr 2007||Robert Webber||Immunoassay method employing monoclonal antibody reactive to human iNOS|
|Clasificación internacional||C12Q1/527, A61K38/00, C12N9/02|
|Clasificación cooperativa||C12Q1/527, A61K38/00, C12N9/0075, C12Y114/13039|
|Clasificación europea||C12Y114/13039, C12N9/00P30C39, C12Q1/527|
|13 Oct 1994||AK||Designated states|
Kind code of ref document: A1
Designated state(s): AU CA JP KR NZ US
|13 Oct 1994||AL||Designated countries for regional patents|
Kind code of ref document: A1
Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
|22 Dic 1994||DFPE||Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)|
|28 Dic 1994||121||Ep: the epo has been informed by wipo that ep was designated in this application|
|7 Ago 1996||122||Ep: pct application non-entry in european phase|
|26 Nov 1996||NENP||Non-entry into the national phase in:|
Ref country code: CA